Apothecary Pharma Recalls Tirzepatide Injections Due to Sterility Risk
Apothecary Pharma LLC is recalling specific lots of Tirzepatide Injection vials due to a lack of assurance of sterility. Check your lot numbers immediately.
Stop using this now
Lack of Assurance of Sterility
What happened, in plain English
Apothecary Pharma LLC has recalled Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial because the product lacks an assurance of sterility. The recall affects 22 vials distributed nationwide within the United States. This is a Class II recall issued on September 24, 2026. Read more at govinfonow.com/recall/1622874-apothecary-pharma-llc-recalls-tirzepatide-injection-18mg-ml-4-ml.
Source Summary by GovInfoNow · govinfonow.com/recall/1622874-apothecary-pharma-llc-recalls-tirzepatide-injection-18mg-ml-4-ml · Published October 21, 2026 · Updated October 21, 2026 · FDA enforcement record: FDA #D-0036-2027
Cite this page
“Apothecary Pharma Recalls Tirzepatide Injections Due to Sterility Risk.” GovInfoNow, updated October 21, 2026. https://govinfonow.com/recall/1622874-apothecary-pharma-llc-recalls-tirzepatide-injection-18mg-ml-4-ml. Based on FDA recall #D-0036-2027 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0036-2027%22&limit=1).
Why it’s dangerous
The primary hazard is a lack of assurance of sterility, meaning the vials may not be free from microorganisms. Using non-sterile injectable medication can lead to serious infections or adverse health reactions when introduced into the body.
Who’s affected
Patients who have been prescribed Tirzepatide Injection from Apothecary Pharma and possess vials with the specific lot numbers listed in the record. Individuals using these non-sterile vials are at risk of infection or other complications from contaminated medication.
How to tell if you have this one
Check your vial for the brand Apothecary Pharma and the NDC 85091-001-18. Verify if the lot number matches one of the following: AP-202622 through AP-202644. The expiration dates (BUD) range from October 7, 2026, to November 26, 2026.
- Brand
Apothecary Pharma- Category
Drug
All 2 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Ongoing- Distribution
Nationwide within the United States
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-0036-2027 | Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18.; Lot #: AP-202622, BUD 07-Oct-2026; AP-202623, BUD 08-Oct-2026; AP-202624, BUD 19-Oct-2026; AP-202625, BUD 10/20/2026; AP-202627, BUD 10/26/2026; AP-202628, BUD 10/27/2026; AP-202629, BUD 10/28/2026; AP-202630, BUD 10/31/2026; AP-202631, BUD 11/01/2026; AP-202632, BUD 11/03/2026; AP-202633, BUD 11/07/2026; AP-202634, BUD 11/08/2026; AP-202635, BUD 11/16/2026; AP-202636, BUD 11/17/2026; AP-202637,BUD 11/18/2026; AP-202638, BUD 11/19/2026; AP-202639, BUD 11/20/2026; AP-202640, BUD 11/21/2026;AP-202641, BUD 11/22/2026; AP-202642, BUD 11/24/2026; AP-202643, BUD 11/25/2026; AP-202644, BUD 11/26/2026 | 22 vials |
| D-0037-2027 | Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, Rx Only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC, 27513, NDC 85091-011-06.; Lot #: AP-202647, BUD 13-Oct-2026 | 1 vial |
What to do — step by step
Stop using the vial
Do not use any Tirzepatide Injection vials that match the recalled lot numbers due to sterility concerns.
Contact your healthcare provider
Reach out to your doctor or pharmacist immediately to discuss alternative treatment options or replacement medication.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 20 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- Added to GovInfoNow
Dates from the agency record only; steps without a date are left out.
Questions people ask
Which specific lot numbers are recalled?
The recalled lots are AP-202622, AP-202623, AP-202624, AP-202625, AP-202627, AP-202628, AP-202629, AP-202630, AP-202631, AP-202632, AP-202633, AP-202634, AP-202635, AP-202636, AP-202637, AP-202638, AP-202639, AP-202640, AP-202641, AP-202642, AP-202643, and AP-202644.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0036-2027 (September 24, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0036-2027 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 21, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.